AstraZeneca

News

ACC25: Mineralys' uncontrolled hypertension drug aces trial

Mineralys looks odds on to become the first drug developer to bring an aldosterone synthase inhibitor to market for uncontrolled hypertension.

News

J&J throws the gauntlet down to AZ with new survival data

New survival data from MARIPOSA for Johnson & Johnson's Rybrevant/Lazcluze combination in lung cancer could spell trouble for AstraZeneca.

News

Building site with thre emen in high viz jackets and protective headweare

AZ builds in China, as J&J ramps up its US investments

AstraZeneca will open its sixth R&D centre in China, while J&J announces four new manufacturing facilities in the US in a major reshoring drive.

News

AstraZeneca buys cell therapy biotech for up to $1bn

AstraZeneca plans to acquire Belgian in vivo cell therapy biotech EsoBiotec and has signed a pair of licensing deals with drug delivery firm Alteogen.

News

EU clears AZ, Ionis' Wainzua for ATTR polyneuropathy

AstraZeneca and Ionis add an EU green light to earlier approvals in the US and UK for ATTR polyneuropathy drug Wainzua, a potential blockbuster.

News

Enhertu extends survival in advanced gastric cancer

Data from a phase 3 trial of Enhertu in advanced HER2-positive gastric cancer could support wider use as a second-line therapy.

ACC25: Mineralys' uncontrolled hypertension drug aces trial

J&J throws the gauntlet down to AZ with new survival data

AZ builds in China, as J&J ramps up its US investments

AstraZeneca buys cell therapy biotech for up to $1bn

EU clears AZ, Ionis' Wainzua for ATTR polyneuropathy

Enhertu extends survival in advanced gastric cancer

J&J's multiple myeloma duo aces phase 3 trial

Discover a new era of healthcare panel engagement: Grounded ...

AstraZeneca

Editor's Picks